Cytosorbents Corporation - Laporan Laba Rugi (TTM)

Cytosorbents Corporation
US ˙ NasdaqCM ˙ US23283X2062

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Cytosorbents Corporation menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 36 41 43 45 44 43 41 38 36 35 35 36 37 31 31 30 31 36 35 36
Change (%) 12.41 4.61 5.20 -1.74 -2.65 -4.42 -8.55 -4.37 -3.86 2.19 2.61 1.92 -16.15 -1.48 -1.89 1.93 16.23 -0.74 2.19
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 11 11 11 11 10 11 11 11 13 14 16 16 14 9 7 6 7 10 11 11
Change (%) 4.07 -3.31 1.80 -3.93 5.70 -0.78 0.99 18.35 6.52 12.30 -0.95 -8.31 -35.85 -20.57 -14.66 14.62 47.55 3.86 4.27
% of Revenue 29.11 26.95 24.91 24.11 23.57 25.59 26.57 29.34 36.31 40.23 44.21 42.68 38.40 29.38 23.68 20.60 23.17 29.41 30.77 31.40
Gross Operating Profit 26 30 32 34 34 32 30 27 23 21 20 21 23 22 23 24 24 25 24 25
Change (%) 15.83 7.54 6.32 -1.05 -5.22 -5.67 -12.00 -13.80 -9.78 -4.62 5.43 9.54 -3.87 6.46 2.07 -1.36 6.78 -2.65 1.27
% of Revenue 70.89 73.05 75.09 75.89 76.43 74.41 73.43 70.66 63.69 59.77 55.79 57.32 61.60 70.62 76.32 79.40 76.83 70.59 69.23 68.60
SG&A 29 32 33 36 37 38 40 38 39 37 36 36 35 38 38 38 37 35 34 35
Change (%) 7.39 5.02 9.37 1.60 4.64 4.01 -4.63 2.37 -6.59 -2.27 -0.20 -0.71 8.37 0.39 -0.81 -3.48 -4.95 -2.43 2.53
% of Revenue 80.44 76.85 77.15 80.21 82.94 89.15 97.01 101.18 108.31 105.22 100.63 97.88 95.35 123.23 125.58 126.96 120.22 98.32 96.64 96.95
R&D 10 9 9 10 13 16 18 19 18 15 15 15 15 16 14 11 10 7 6 6
Change (%) -9.01 3.60 14.17 24.07 26.70 11.97 2.64 -5.16 -15.32 -0.19 -3.41 3.15 3.73 -12.62 -15.78 -16.54 -27.80 -8.44 -4.07
% of Revenue 26.54 21.49 21.28 23.09 29.16 37.95 44.46 49.90 49.48 43.58 42.57 40.07 40.55 50.17 44.50 38.20 31.28 19.43 17.92 16.82
OpEx 50 51 53 57 60 66 69 68 70 66 66 66 65 63 59 56 53 52 51 52
Change (%) 3.48 2.98 8.67 4.63 9.57 5.19 -1.82 2.88 -6.37 1.31 -1.10 -1.65 -2.45 -5.86 -5.94 -4.16 -2.08 -1.97 2.08
% of Revenue 136.10 125.29 123.34 127.41 135.67 152.69 168.04 180.42 194.10 189.04 187.42 180.63 174.30 202.78 193.76 185.76 174.66 147.16 145.33 145.17
Operating Income -13 -10 -10 -12 -16 -23 -28 -30 -34 -31 -31 -29 -28 -32 -29 -26 -23 -17 -16 -16
Change (%) -21.24 -3.46 23.56 27.86 43.80 23.42 8.08 11.90 -9.03 0.33 -5.35 -6.08 15.99 -10.13 -10.26 -11.26 -26.59 -4.58 1.84
% of Revenue -36.10 -25.29 -23.34 -27.41 -35.67 -52.69 -68.04 -80.42 -94.10 -89.04 -87.42 -80.63 -74.30 -102.78 -93.76 -85.76 -74.66 -47.16 -45.33 -45.17
Interest Expense -1 -1 -1 -1 -0 -0 -0 -0 -0 -0 -0 -1 -1 -2 -2
Change (%) 4.27 -24.60 -31.35 -41.92 13.97 46.77 49.43 -35.79 169.20 203.18 69.10 42.78 21.80
% of Revenue -3.16 -2.93 -2.11 -1.38 -0.81 -0.18 -0.20 -0.29 -0.51 -0.33 -0.91 -2.70 -3.93 -5.65 -6.74
Net Income -11 -8 -9 -10 -16 -25 -29 -36 -41 -33 -31 -26 -23 -29 -28 -26 -19 -21 -16 -10
Change (%) -29.45 9.12 21.17 53.72 54.17 19.54 21.12 16.30 -20.65 -5.00 -15.16 -11.37 24.78 -4.23 -6.63 -26.23 7.39 -22.25 -38.75
% of Revenue -30.45 -19.11 -19.94 -22.96 -35.93 -56.89 -71.16 -94.25 -114.61 -94.59 -87.94 -72.71 -63.23 -94.09 -91.46 -87.04 -63.00 -58.21 -45.59 -27.32

Source: Capital IQ

Other Listings
DE:HQE1 € 0.81
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista